Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Nextstellis® (drospirenone/estetrol) – New drug approval

Mayne Pharma and Mithra Pharmaceuticals announced the FDA approval of Nextstellis (drospirenone/estetrol), for use by females of reproductive potential to prevent pregnancy. April 16, 2021

bamlanivimab – Emergency use authorization revoked

The FDA revoked the emergency use authorization (EUA) for Eli Lilly’s bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and certain pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 vial testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. April 16, 2021

J&J COVID-19 Vaccine – Use Paused Due to Possible Safety Concern

The CDC and FDA recommended a pause in the use of the Johnson & Johnson (J&J) coronavirus vaccine out of an abundance of caution due to six reports of blood clots. April 13, 2021

Lyrica® CR (pregabalin) – First-time generic

Novadoz/MSN Pharmaceuticals and Alvogen launched AB-rated generic versions of Pfizer’s Lyrica CR (pregabalin) extended-release tablets. April 13, 2021

Evekeo ODT™ (amphetamine sulfate) – Expanded indication, new strength

The FDA approved Arbor Pharmaceuticals’ Evekeo ODT (amphetamine sulfate), for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 3 to 17 years of age. April 16, 2021

Opdivo® (nivolumab) – New indication

Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. April 16, 2021

Trodelvy® (sacitzumab govitecan-hziy) – New indication

Gilead Sciences announced the FDA approval of Trodelvy (sacituzumab govitecan-hziy), for the treatment of locally advanced or metastatic urothelial cancer (UC) in adult patients who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. April 13, 2021

Xolair® (omalizumab) – Updated dosing

Genentech announced the FDA approval of Xolair (omalizumab) prefilled syringe for self-injection across all its approved indications. April 12, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.